Diuretic Exposure in Premature Infants from 1997 to 2011

Abstract

Objective Diuretics are often prescribed off-label to premature infants, particularly to prevent or treat bronchopulmonary dysplasia. We examined their use and safety in this group.

Study Design Retrospective cohort study of infants < 32 weeks gestation and < 1,500 g birth weight exposed to diuretics in 333 neonatal intensive care units from 1997 to 2011. We examined use of acetazolamide, amiloride, bumetanide, chlorothiazide, diazoxide, ethacrynic acid, furosemide, hydrochlorothiazide, mannitol, metolazone, or spironolactone combination. Respiratory support and fraction of inspired oxygen on the first day of each course of diuretic use were identified.

Results About 37% (39,357/107,542) infants were exposed to at least one diuretic; furosemide was the most commonly used (93% with ≥ 1 recorded dose), followed by spironolactone, chlorothiazide, hydrochlorothiazide, bumetanide, and acetazolamide. About 74% patients were exposed to one diuretic at a time, 19% to two diuretics simultaneously, and 6% to three diuretics simultaneously. The most common combination was furosemide/spironolactone, followed by furosemide/chlorothiazide and chlorothiazide/spironolactone. Many infants were not receiving mechanical ventilation on the first day of each new course of furosemide (47%), spironolactone (69%), chlorothiazide (61%), and hydrochlorothiazide (68%). Any adverse event occurred on 42 per 1,000 infant-days for any diuretic and 35 per 1,000 infant-days for furosemide. Any serious adverse event occurred in 3.8 for any diuretic and 3.2 per 1,000 infant-days for furosemide. The most common laboratory abnormality associated with diuretic exposure was thrombocytopenia.

Conclusion Despite no Food and Drug Administration (FDA) indication and little safety data, over one-third of premature infants in our population were exposed to a diuretic, many with minimal respiratory support.

Keywords

bronchopulmonary dysplasia - diuretic - safety - drug

• References

• 1 Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2011; 9 (9) CD001453
• 2 Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2011; 9 (9) CD001817
• 3 Young TE, Kruyer LS, Marshall DD, Bose CL ; The North Carolina Neonatologists Association. Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. Pediatrics 1999; 104 (2) e17
• 4 Lemons JA, Bauer CR, Oh W , et al; Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107 (1) E1
• 5 Singer L, Yamashita T, Lilien L, Collin M, Baley J. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics 1997; 100 (6) 987-993
• 6 Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999; 104 (6) 1345-1350
• 7 Oh W, Poindexter BB, Perritt R , et al; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147 (6) 786-790
• 8 Hornik CP, Herring AH, Benjamin Jr DK , et al; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013; 32 (7) 748-753
• 9 Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics 2013; 131 (4) 716-723
• 10 Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276 (7) 357-368
• 11 Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 1978; 92 (6) 982-984
• 12 Brion LP, Yong SC, Perez IA, Primhak R. Diuretics and chronic lung disease of prematurity. J Perinatol 2001; 21 (5) 269-271
• 13 Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007; 4 (4) CD000501
• 14 Schmidt B, Roberts RS, Davis P , et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354 (20) 2112-2121
• 15 Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009; 1 (1) CD001146
• 16 Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics 2007; 120 (5) 1088-1099
• 17 Ballard RA, Truog WE, Cnaan A , et al; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355 (4) 343-353
• 18 Swan KN, Ahlfeld SK, Smith PB, Laughon MM. Review of randomized controlled trials for the prevention of bronchopulmonary dysplasia. Poster presented at: Pediatric Academic Societies Annual Meeting, May 4, 2013. Washington, DC
• 19 Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf 2004; 3 (2) 81-83
• 20 Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290 (7) 905-911
• 21 Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88 (9) 965-968
• 22 Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit [in French]. Arch Pediatr 2000; 7 (2) 143-147
• 23 Andersen DH, Blanc WA, Crozier DN, Silverman WA. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956; 18 (4) 614-625
• 24 Stewart DJ. The effects of tetracyclines upon the dentition. Br J Dermatol 1964; 76: 374-378
• 25 Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959; 261: 1318-1321
• 26 Yeh TF, Lin YJ, Huang CC , et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101 (5) E7
• 27 Laughon MM, Benjamin Jr DK, Capparelli EV , et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011; 4 (5) 643-652
• 28 Ekins-Daukes S, Helms PJ, Taylor MW, McLay JS. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol 2005; 60 (2) 145-149
• 29 Mukattash T, Hawwa AF, Trew K, McElnay JC. Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 2011; 67 (5) 449-461